Business Wire

Ant Group Chairman Eric Jing Outlines Strategy for Inclusive AI, Collaboration on Tokenised Settlement

14.11.2025 11:15:00 CET | Business Wire | Press Release

Share

Eric Jing, Chairman of Ant Group, said the company's focus is on putting new payment and operation tools powered by AI and tokenisation technology in the hands of SMEs, to fully embrace the next wave of global productivity revolution.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114239737/en/

Ant Group Chairman Eric Jing (second from right) shares insights during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025.

“We are passionate about using frontier technology to support SMEs and the use of AI will really uplift inclusion,” Jing said during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025.

Jing was joined by Agustín Carstens, Former General Manager, Bank for International Settlements (BIS); Ravi Menon, Chairman of the Board of Directors, Global Finance & Technology Network (GFTN); Ambassador (Climate Action), Singapore & Former Managing Director, Monetary Authority of Singapore, GFTN, and Dr. Razeen Sally who moderated the panel.

From Agentic Payment to Agentic Finance: A Virtual CFO, and COO for SMEs

On the consumer front, Jing expects the rise of personalised AI financial managers and advisors. On the business front, “Agentic payment is one of the most important forces driving agentic commerce and agentic systems,” Jing said. Ant will focus on democratising AI for SMEs at a time when small businesses engaged in global trade face increasingly complex payment and risk environments.

“Many SMEs may not have sophisticated digital skills or a large workforce to support them in doing business, and this is where AI agents can really play a role in helping them to navigate the landscape,” Jing said.

Antom, the merchant payment and digitisation services arm of Ant International, is using Antom Copilot to support payment integration, merchant onboarding, risk management settings, and chargeback response. Copilot cuts payment integration time by over 90%, boosts chargeback winning rates by 3 percentage points, and shortens chargeback resolution time by 46 percent.

During the Singapore FinTech Festival 2025, Antom also launched EPOS360, an app that brings point-of-sale (POS) system, payments, banking, lending, and growth support together to help micro, small and medium‑sized enterprises (MSMEs) move from setup to scale efficiently.

“Agentic AI will act like your COO, your CFO. They are stepping in as virtual financial and operational planners and implementers for SMEs, enabling them to compete globally,” Jing said.

He added that the rise of agentic payments and multi-agent systems are already on track, where autonomous AI agents collaborate to execute complex end-to-end transactions.

Collaboration with MAS on AI and Blockchain is an Exemplar of Public-Private Collaboration

“The tokenisation of money that enables global real-time settlement across borders will be particularly beneficial to SMEs and companies doing global trade,” Jing said. “On such important projects, it is necessary to have policy leadership from regulators like the Monetary Authority of Singapore, who provides institutional clarity and brings together an industry ecosystem of collaboration.”

Ant International’s deep collaboration with the Monetary Authority of Singapore (MAS) through key initiatives like Project Guardian and PathFin.ai sets an exemplary model of public-private partnership, especially when blockchain and AI have emerged as global themes.

“We are honoured to participate in the Monetary Authority of Singapore’s regulatory sandboxes. They provide the clarity and certainty needed to responsibly deploy cutting-edge technologies while managing risks,” said Jing. “This new technology is up and coming, we cannot shy away from it. Instead, the right way is to harness the technology to get the benefits while keeping in mind the potential risks and challenges.”

Under Project Guardian, Ant International has contributed to pilot efforts in tokenised money and cross-border settlements, demonstrating how real-time, transparent and credible blockchain-based payments can benefit SMEs engaged in global trade.

Through MAS’ PathFin.ai programme, Ant International is also actively engaging in knowledge exchange on AI implementations. Jing highlighted Ant International’s Falcon Time-Series Transformer (TST) Model — an 8.5-billion-parameter AI model designed for FX and liquidity forecasting. The model has significantly improved accuracy in predicting cash flow and liquidity, helping businesses reduce hedging costs in today’s volatile global economy.

“Through participating in sandboxes, we see benefits and opportunities to improve our products before rolling them out. It has really been a pleasure to be part of that – MAS is taking a very proactive role and it’s enormously valuable,” said Jing.

Ant International, which became independent in 2024, is headquartered in Singapore. The company now collaborates with over 1,400 institutional partners and provides global payment, settlement and digitisation services to 150 million merchants, and a network of global wallets and national QR schemes that together serve over 1.8 billion consumer accounts.

—END—

About Ant International

With headquarters in Singapore and main operations across Asia, Europe, the Middle East and Latin America, Ant International is a leading global digital payment, digitisation and financial technology provider. Through collaboration across the private and public sectors, our unified techfin platform supports financial institutions and merchants of all sizes to achieve inclusive growth through a comprehensive range of cutting-edge digital payment and financial services solutions. To learn more, please visit https://www.ant-intl.com/

View source version on businesswire.com: https://www.businesswire.com/news/home/20251114239737/en/

Contacts

For media enquiries, please contact
pr@ant-intl.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye